Active Von Hippel Lindau Tumor Suppressor (vHL)

HRCA1; RCA1; VHL1; Von Hippel-Lindau Syndrome

  • Active Von Hippel Lindau Tumor Suppressor (vHL) Packages (Simulation)
  • Active Von Hippel Lindau Tumor Suppressor (vHL) Packages (Simulation)
  • APJ769Hu01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

ACTIVITY TEST of the Active Von Hippel Lindau Tumor Suppressor (vHL)

USAGE of the Active Von Hippel Lindau Tumor Suppressor (vHL)

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE of the Active Von Hippel Lindau Tumor Suppressor (vHL)

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY of the Active Von Hippel Lindau Tumor Suppressor (vHL)

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Related products

Catalog No. Organism species: Homo sapiens (Human) Applications (RESEARCH USE ONLY!)
UAPJ769Hu01 Active Von Hippel Lindau Tumor Suppressor (vHL) Cell culture; Activity Assays.
URPJ769Hu01 Recombinant Von Hippel Lindau Tumor Suppressor (vHL) Positive Control; Immunogen; SDS-PAGE; WB.
GUESTBOOK